65,437 trials
Precocious Puberty
Primary: Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L — 31; 6; 31; 3 participants
Colorectal Cancer Screening · Prevention & Control
Primary: Colorectal Cancer Screening Completion. — 304; 283; 10; 31 participants — p=<0.05
Neoplasms, Breast
Primary: Progression-Free Survival (PFS) — 12.0; 8.1 weeks — p=0.008
Osteoarthritis
Primary: Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) — 1.3; 2.4 Percentage of participants — p=0.0003
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 — 51.8; 41.3 Percentage of Patients
Nicotine Dependence
Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO
Atherosclerotic Vascular Disease
Primary: Percent Reduction From Baseline in TBRmeanmax of the Qualifying Segment — 1.4; 5.8 Percent reduction — p=0.006
Narcolepsy
Primary: Daytime Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) — -2.72; 0.58; -0.53; 2.68 Minutes — p=<0.001
Vertebral Body Compression Fractures (VCFs)
Primary: Absolute Vertebral Body Height Restoration as a Percent (Post-procedure Change From Baseline) — 9.72; 11.77; 8.14; 9.07 percent change — p=0.430
Fibromyalgia
Primary: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF). — 27.3; 46.2; 39.3; 72.7…
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 — 74.9; 65.2 Percentage of Patients
Tobacco Dependence
Primary: 6 Month Self-reported Abstinence From Smoking — 50; 52; 45; 75 participants
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With at Least 70% Reduction in ADHD Symptoms as Measured by Change in ADHD Rating Scale From First to Last Visit — 6; 2 participants
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib — 1423; 3806; 6569 ng*hr/mL
Necrotizing Enterocolitis · Intra-abdominal Infection
Primary: Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study…